Mana Keihanian, MD
Cardiovascular Disease · Draper, UTNPI 1699079434
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,060 of the $4,790 with a category attached, or 84.8%. 24 manufacturers reported payments, led by Boston Scientific at 38.5% of the total. 2025 is the largest year on record at $1,644, more than ten times the $129 reported in 2020.
Across 181 payments — averaging $26.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Pfizer$447
- E.r. Squibb & Sons, L.L.C.$415
- Novartis$376
- Amgen$278
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$240
- plus $1K from 18 others
What the payments were for
- Travel & lodging$73015%
- Food & beverage$4,06085%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 33 | $1,844 |
| Pfizer | 26 | $447 |
| E.r. Squibb & Sons, L.L.C. | 21 | $415 |
| Novartis | 19 | $376 |
| Amgen | 17 | $278 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $240 |
| Johnson & Johnson | 13 | $211 |
| Merck | 12 | $202 |
| Boehringer Ingelheim | 12 | $186 |
| Actelion Pharmaceuticals US, Inc. | 3 | $104 |
| Baxter Healthcare | 4 | $99 |
| Impulse Dynamics (USA) Inc. | 2 | $67 |
| Alnylam Pharmaceuticals Inc. | 2 | $57 |
| Heartflow, Inc. | 2 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Abbott | 1 | $28 |
| Edwards Lifesciences | 1 | $28 |
| AstraZeneca | 2 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Itamar Medical Inc | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$1,024
- LifeVest$144
- WATCHMAN FLX$107
- WATCHMAN Access System$106
How this compares
$4,790 in reported general payments places this provider in the 70th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 150 | $178,863 |
| FarxigaDapagliflozin Propanediol | 43 | $51,688 |
| Repatha SureclickEvolocumab | 44 | $40,283 |
| XareltoRivaroxaban | 26 | $37,768 |
| EntrestoSacubitril/Valsartan | 23 | $33,937 |
| JardianceEmpagliflozin | 18 | $18,611 |
| Repatha SyringeEvolocumab | 36 | $14,443 |
| Metoprolol Succinate | 670 | $7,984 |
| Atorvastatin Calcium | 476 | $3,996 |
| Rosuvastatin Calcium | 338 | $3,274 |
| Ranolazine ErRanolazine | 26 | $2,207 |
| Omeprazole | 99 | $1,871 |
| Carvedilol | 181 | $1,283 |
| Lisinopril | 231 | $1,232 |
| Hydralazine Hcl | 94 | $1,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $447 | $178,863150 claims |
| AstraZenecaFarxiga | $25 | $51,68843 claims |
| Johnson & JohnsonXarelto | $211 | $37,76826 claims |
| NovartisEntresto | $376 | $33,93723 claims |
| Boehringer IngelheimJardiance | $186 | $18,61118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 131 cardiovascular disease providers in Utah.
Other cardiovascular disease in Draper
- Andrew BehuninDraper$192K
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
- Joseph MuhlesteinMurray$65K
- Hannah RaaschSalt Lake City$62K
- Divya Ratan VermaMurray$47K
- Daniel VarelaSt George$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.